HARCP

HEROIN ADDICTION AND
RELATED CLINICAL PROBLEMS

The official journal of
EUROPAD - European Opiate Addiction Treatment Association
WFTOD - World Federation for the Treatment of Opioid Dependence
Editor: Icro Maremmani, MD - Pisa, Italy, EU
Associate Editors:
Thomas Clausen, MD - Oslo, Norway
Pier Paolo Pani, MD - Cagliari, Italy, EU
Marta Torrens, MD - Barcelona, Spain, EU
Statistical Editor:
Mario Miccoli, PhD - Pisa, Italy, EU

HARCP Archives

Browse by article Browse by volume    

Heroin Addiction and Related Clinical Problems: 2005, 07, 1 (pages: 7 - 18)

Buprenorphine induction and stabilisation in the treatment of opiate dependence

Doran C., Holmes J., Ladewig D., Ling W.

Summary: Many early trials of buprenorphine in opiate dependence used fixed doses and slow induction protocols. However, more recent data show that subjects requiring higher doses need to be stabilised more rapidly. Analysis of ten trials suggests a relationship between days taken to reach a 6 mg buprenorphine tablet equivalent dose and retention of subjects at 4 weeks. Recent US studies show that dosage can be stepped up quickly, e.g. 8 mg on Day 1, 16 mg on Day 2. Maintenance dosage should then be adjusted to meet patients' clinical needs; fixed dose studies ignore the breadth of buprenorphine's effective dose range.

 

AU-CNS Associazione per l’Utilizzo delle Conoscenze Neuroscientifiche a fini Sociali
Association for the Application of Neuroscientific Knowledge to Social Aims
Via XX Settembre, 83 – 55045 PIETRASANTA (Lucca) - Italy
P. IVA 01681650469 – Codice Fiscale 94002580465 Reserved Area
Tel/Phone: 0584 - 790073 - Email: info@heroinaddictionrelatedclinicalproblems.org		 Start of page